Technical Data
A0004-75A
ABIN-1 (A-20 binding Inhibitor of Nuclear Factor-kappaB (NF-kB) Activation)
Description:
A20-binding inhibitor of NFkB activation (ABIN-1) is involved in NFkB-dependent gene expression and plays an important role in numerous cellular processes including stress responses, inflammation and cell proliferation. ABIN-1 increases cell surface CD4 (T4) antigen expression, and it interacts with HIV-1 matrix protein and is packaged into virions. Overexpression of ABIN-1can .inhibit viral replication. ABIN-1 may also regulate matrix nuclear localization, both nuclear import of PIC (Preintegration complex) and export of GAG polyprotein and viral genomic RNA during virion production. ABIN-1 is strongly expressed in peripheral blood lymphocytes, spleen and skeletal muscle, and is weakly expressed in the brain.

Applications:
Suitable for use in ELISA, Immunoprecipitation and Western Blot. Other applications have not been tested.

Recommended Dilutions:
ELISA (Immunogen): 0.1-1ug/ml
Immunoprecipitatio (Human): 7-10ug/test
Western Blot (Human): 1-3ug/ml
Optimal dilutions to be determined by the researcher.

Positive Control:
HEK-293 cell lysate.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG2a,k6A2Affinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanMouse
Concentration:
~0.5mg/ml
Immunogen:
Synthetic peptide corresponding to the N-terminal region of the human, mouse and rat ABIN-1 protein.
Purity:
Purified by Protein A chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 0.1% sodium azide.
Specificity:
Recognizes the ~80kD human ABIN-1 protein. Bands of unknown origin at ~180kD and >250kD were observed in Western Blots using HEK-293 cell lysates. Species Sequence Homology: mouse and rat 100%.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Fukushi M, et al. FEBS Lett 442:83-88, 1999. 2. Heyninck K, et al. FEBS Lett 563:135-140, 2003.